Vericel (VCEL)
(Delayed Data from NSDQ)
$51.65 USD
+0.10 (0.19%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $51.70 +0.05 (0.10%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$51.65 USD
+0.10 (0.19%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $51.70 +0.05 (0.10%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Zacks News
Will Vericel (VCEL) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Vericel (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Vericel (VCEL) a New Buy Stock
by Zacks Equity Research
Vericel (VCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vericel (VCEL) Tops on Q4 Earnings & Sales, Stock Up
by Zacks Equity Research
Vericel (VCEL) beat estimates for earnings as well as revenues in fourth-quarter 2018. Shares up in pre-market trading.
What's in Store for Vericel (VCEL) This Earnings Season?
by Zacks Equity Research
On Vericel's (VCEL) fourth-quarter conference call, investor focus will be on the sales figures of the company's two approved medicines -- MACI and Epicel.
Bull or Bear: Your Investment Strategy for 2019
by Sejuti Banerjea
Whether you're a bull or a bear, it may be a good idea to go defensive about now.
Zacks.com featured highlights include: Alteryx, Vericel, Mitek and Materialise
by Zacks Equity Research
Zacks.com featured highlights include: Alteryx, Vericel, Mitek and Materialise
4 Stocks With Recent Price Strength to Maximize Your Gains
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Has Vericel (VCEL) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (VCEL) Outperforming Other Medical Stocks This Year?
5 Nasdaq Composite Stocks That Braved the Index's Bloodbath
by Nalak Das
Despite a plummeting Nasdaq Composite, a few companies have survived the turbulence because of their internal strengths.
4 Healthcare Stocks That Popped More Than 100% in 2018
by Sapna Bagaria
Players in the Healthcare sector gained from aging population, expanding government business, technological investment, strong demand for its product and services and industry consolidation.
Zacks.com featured highlights include: TEGNA, Vericel, Mobile Mini and Splunk
by Zacks Equity Research
Zacks.com featured highlights include: TEGNA, Vericel, Mobile Mini and Splunk
4 Best Stocks That Flaunt Superb Earnings Acceleration
by Tirthankar Chakraborty
Studies show that a majority of successful stocks see acceleration in earnings before an uptick in the stock price.
Four Biotech Stocks That Popped More Than 50% in 2018
by Zacks Equity Research
The biotech sector has failed to impress the investors in 2018 which has underperformed the broader S&P 500 market. However, we provide four biotech companies which performed well in this scenario.
Vericel (VCEL) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
Vericel (VCEL) closed the most recent trading day at $17.10, making no change from the previous trading session.
Has Vericel (VCEL) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (VCEL) Outperforming Other Medical Stocks This Year?
Small-Cap ETFs & Stocks to Outperform This Holiday Season (Revised)
by Sweta Killa
The outperformance of the small-caps seems to hold true this year given that these pint-sized stocks are well insulated from international headwinds.
Zacks.com highlights: Helen of Troy, Vericel, Mobile Mini and Logitech International
by Zacks Equity Research
Zacks.com highlights: Helen of Troy, Vericel, Mobile Mini and Logitech International
4 Best Stocks to Buy for Superb Earnings Acceleration
by Tirthankar Chakraborty
Studies have shown that a majority of successful stocks had seen acceleration in earnings before an uptick in the stock price.
Zacks.com highlights: Vericel, Mitek, Vanda Pharmaceuticals, Mosaic and Spirit Airlines
by Zacks Equity Research
Zacks.com highlights: Vericel, Mitek, Vanda Pharmaceuticals, Mosaic and Spirit Airlines
The Zacks Analyst Blog Highlights: Vericel, Malibu Boats, Upland Software, QuinStreet and eGain
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vericel, Malibu Boats, Upland Software, QuinStreet and eGain
Small-Cap ETFs & Stocks to Outperform This Holiday Season
by Sweta Killa
The outperformance of the small-caps seems to hold true this year given that these pint-sized stocks are well insulated from international headwinds.
5 Stocks With Recent Price Strength to Strengthen Portfolio
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Top Ranked Momentum Stocks to Buy for November 9th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 9th
Will Vericel (VCEL) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Vericel (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel
by Zacks Equity Research
Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel